IP Library Granted Patent US 10,744,235
Granted Patent B2
US 10,744,235 · App. 14/300,607 · Granted Aug 18, 2020

Degradable removable implant for the sustained release of an active compound

Inventors: Lieven Elvire Colette Baert (Bruges, BE); Iksoo Chun (Princeton, NJ); Guenter Kraus (Sint-Katelijne-Waver, BE); Deborah M. Schachter (Edison, NJ); Qiang Zhang (Annandale, NJ)
Assignee: Janssen Sciences Ireland Unlimited Company
A61L31/148A61K9/0024A61K9/0092A61K9/14A61K9/5031A61K31/34A61K31/343A61K31/505A61K45/06A61L31/146A61K9/06A61K9/5084
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,744,235
App. No.
14/300,607
Granted
Aug 18, 2020
Kind
B2
Abstract

A degradable, removable, pharmaceutical implant for the sustained release of one or more drugs in a subject, wherein the pharmaceutical implant is composed of a tube comprising an outer wall made of a degradable polymer completely surrounding a cavity, wherein the outer wall has a plurality of openings and wherein the cavity contains one or more sets of micro-particles, which micro-particles contain an active agent or a combination of two or more active agents, and wherein the size of the microparticles is selected such that the majority of the microparticles cannot pass through the openings.

Claims (11)

1. A degradable, removable, pharmaceutical subcutaneous implant for the sustained release of one or more drugs in a subject, comprising

a tube that is defined by an outer wall,

wherein the outer wall is fabricated from poly(dioxanone); has a plurality of openings on its surface; and completely surrounds a cavity,

and wherein the cavity contains one or more sets of microparticles embedded in a hydrogel, wherein at least one set of the microparticles comprises rilpivirine and a copolymer of lactide and glycolide, and

wherein the size of the microparticles is selected such that the majority of the microparticles cannot pass through the openings.

2. The implant of claim 1 , wherein the cavity contains two or more sets of microparticles.

3. The implant of claim 1 , wherein the polymer used to fabricate the microparticles is copolymers of lactide and glycolide.

4. The implant of claim 1 , wherein the polymer used to fabricate the microparticles is a copolymer of lactide and glycolide with a mole percent of lactide that ranges from 86% to 50%.

5. The implant of claim 1 , wherein at least one set of microparticles comprises a nucleoside reverse transcriptase inhibitor.

6. The implant of claim 1 , wherein at least one set of microparticles comprises a nucleotide reverse transcriptase inhibitor.

7. The implant of claim 1 , wherein at least 85% (w/w) of the microparticles are locked in the cavity of the implant.

Assignments (3)
CHANGE OF NAME Recorded Jul 27, 2022
From: JANSSEN SCIENCES IRELAND UC
To: JANSSEN SCIENCES IRELAND UNLIMITED COMPANY
Reel/Frame 060989/0661 →
CHANGE OF NAME Recorded Jun 9, 2020
From: JANSSEN SCIENCES IRELAND UC
To: JANSSEN SCIENCES IRELAND UNLIMITED COMPANY
Reel/Frame 052880/0204 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2015
From: JANSSEN R & D IRELAND
To: JANSSEN SCIENCES IRELAND UC
Reel/Frame 035496/0382 →